Delcath Systems (DCTH) Announces Phase III Melanoma Study Fully Enrolled
More News related to DCTH
- Delcath Systems, Inc. Sponsors Satellite Session at World Meeting of Melanoma/Skin Cancer Centers
- Delcath Systems Reports Substantial Progress
- Delcath Systems Announces Completion of Public Offering
- Delcath Systems to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Delcath Systems (DCTH) Prices 8.5M Share Offering at $3.60/Share
More News related to Corporate News
- Hydrogenics Resumes Trading Under NASDAQ Symbol "HYGS"
- Varian Medical (VAR) to Highlight its New Range of Detectors at Annual RSNA Meeting in Chicago
- Manulife (MFC) Confirms No Exposure to Dubai World
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Seiko Epson to Transfer Sales Function of Small and Medium-Sized TFT LCD Business to Sony (SNE)
Delcath Systems, Inc. (NASDAQ: DCTH) announced today that its pivotal Phase III Metastatic Melanoma Trial has met its goal of 92 patients and is fully enrolled. This clinical study is evaluating the Delcath PHP System for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver.
With the achievement of complete enrollment, the company remains on-track for a FDA submission of its Delcath PHP System with melphalan in 2010. Trial enrollment will continue for the near-term to include additional patients that have begun the evaluation process and may be eligible to participate.
Related Categories
Corporate NewsStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
